AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well AZD2171 works in treating patients with recurrent
ovarian, peritoneal, or fallopian tube cancer. AZD2171 may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor